News

GSK bids for Human Genome Science
Enlarge image

BusinessUK

GSK bids for Human Genome Science

20.04.2012 - Human Genome Science Inc. rebuffs an unsolicited takeover bid from GlaxoSmithKline.

London – European pharma companies have had no luck with US M&A activities recently. First Roche walked away from its acquisition of gene sequencing specialist Illumina Inc.  Now Human Genome Science Inc. (HGS) has rejected an unsolicited US-$2.59bn bid from GlaxoSmithKline. Great Britain’s largest drugmaker offered US-$13 per share in cash, an 81% premium on HGS’s closing share price on March 18.

In spite of that, the Maryland-based biotech said "does not reflect the value inherent in HGS“ and therefore rebuffed the offer. Goldman, Sachs & Co. and Credit Suisse will now advise it on "strategic alternatives" including a possible sale of the company. Obviously, the door for the deal has not closed yet. According to HGS, Glaxo "has been invited to participate in this process“.

GSK's chief executive, Sir Andrew Witty, said he was disappointed that Human Genome had rejected his offer without discussion. "Having worked together with Human Genome Sciences for nearly 20 years, we believe there is clear strategic and financial logic to this combination for both companies and our respective shareholders – and that now is the appropriate time in the evolution of our relationship for our two companies to combine." GSK’s move has been seen as a bet on the sales prospects of several drugs the companies are developing or marketing together. The results for a clinical trial with a diabetes drug are expected for this summer. Last year, the two companies jointly launched Benlysta, the first new drug for lupus in fifty years. 

http://www.european-biotechnology-news.com/news/news/2012-02/gsk-bids-for-us-biotech-hgs.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.05 CHF25.00%
  • NEUROSEARCH A/S (DK)2.58 DKK6.61%
  • VERONA PHARMA (UK)3.50 GBP6.06%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • SAREUM HOLDINGS (UK)0.23 GBP-8.00%

TOP

  • EPIGENOMICS (D)4.62 EUR100.0%
  • TRANSGENE (F)3.24 EUR27.6%
  • VERONA PHARMA (UK)3.50 GBP22.8%

FLOP

  • BIONOR PHARMA (N)0.92 NOK-39.5%
  • PROTHENA PLC (IE)36.77 USD-37.7%
  • CELLECTIS (F)18.99 EUR-31.2%

TOP

  • KARO BIO (S)27.70 SEK3857.1%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.42 EUR302.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.90 SEK-85.4%
  • BIOTEST (D)14.31 EUR-84.3%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 04.02.2016